Vertex Shares Surge on Analyst Upgrade, Pipeline Expansion in Focus
Vertex Pharmaceuticals shares climbed 5.7% following an upgrade from Oppenheimer, driven by its 2026 revenue outlook and expanding pipeline in gene-editing, pain, and kidney therapies.
Analysis
